Key facts
- This page summarizes Kevin Haas's Form 3 filing for Vincerx Pharma, Inc. (VINC).
- 0 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2025, 16:29.
Kevin Haas - 20 Dec 2024 Form 3 Insider Report for Vincerx Pharma, Inc. (VINC)
- Reporting relationship
- Acting Chief Financial Officer
- Issuer ticker
- VINC
- Reported as of
- 20 Dec 2024
- Net transaction value
- $0
- Reporting owner signature
- By: /s/ Kevin Haas
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Kevin Haas filed Form 3 for Vincerx Pharma, Inc. (VINC) on 06 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VINC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 42,776
- Date
- 20 Dec 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,450
- Exercise price
- $0.5500
- Footnotes
- F1
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,000
- Exercise price
- $0.5500
- Footnotes
- F2
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,000
- Exercise price
- $0.5500
- Footnotes
- F3
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,000
- Exercise price
- $0.5500
- Footnotes
- F4
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,125
- Exercise price
- $0.5500
- Footnotes
- F5
VINC
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,875
- Exercise price
- $0.5500
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
One-third (1/3) vests on February 14, 2023, with the remainder vesting in twenty-four equal monthly installments thereafter.
Footnote F2
Option vests in twenty-four equal monthly installments starting from August 25, 2022.
Footnote F3
Option vests in twenty-four equal monthly installments starting from November 15, 2022.
Footnote F4
Option vests in twenty-four equal monthly installments starting from February 15, 2023.
Footnote F5
One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.
SEC remarks
Exhibit List: Exhibit 24 - Power of Attorney